Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology & Blood Diseases Hospital; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Condition: Multiple Myeloma Intervention: Other: Chemotherapy and/or autologous hematopoietic stem cell transplantation Sponsor: Qilu Hospital of Shandong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
ConclusionCurrently, there is no commonly accepted standard for salvage chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic burden, achieve the best possible remission, and perform a hemopoietic stem-cell transplantation. Thus, in patients withFLT3-ITD mutation, the comparison of quizartinib with intensive salvage therapy versus chemotherapy alone appears as a logical consequence in terms of efficacy and safety.Ethics and disseminationEthical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and pres...
Source: Trials - September 15, 2023 Category: Research Source Type: clinical trials
